Will new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug Share XWill new data make Pfizer’s Lorbrena a ‘no-brainer’ in early lung cancer?https://pharmaphorum.com/news/will-new-data-make-pfizers-lorbrena-a-no-brainer-in-early-lung-cancer/
